1. 1) Nelson, D. R., Koymans, L., Kamataki, T., Stegeman, J. J., Feyereisen, R., Waxman, D. J., Waterman, M. R., Gotoh, O., Coon, M. J., Estabrook, R. W., Gunsalus, I. C. and Nebert, D. W.: P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics, 6: 1–42 (1996).
2. 2) Thummel, K. E. and Wilkinson, G. R.: In vitro and in vivo drug interactions involving human CYP3A. Annu. Rev. Pharmacol. Toxicol., 38: 389–430 (1998).
3. 3) Domanski, T. L., Finta, C., Halpert, J. R. and Zaphiropoulos, P. G.: cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450. Mol. Pharmacol., 59: 386–392 (2001).
4. 4) Shimada, T., Yamazaki, H., Mimura, M., Inui, Y. and Guengerich, F. P.: Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther., 270: 414–423 (1994).
5. 5) Li, A. P., Kaminski, D. L. and Rasmussen, A.: Substrates of human hepatic cytochrome P450 3A4. Toxicology, 104: 1–8 (1995).